14 October 2023 : Clinical Research
Influence of Age, Gender, Frailty, and Body Mass Index on Serum IL-17A Levels in Mature Type 2 Diabetic Patients
Zvonimir Bosnić1ABEF, František Babič
2CDEG*, Thomas Wittlinger34DEG, Viera Anderková2C, Ines Šahinović 5B, Ljiljana Trtica Majnarić16ABDEF
DOI: 10.12659/MSM.940128
Med Sci Monit 2023; 29:e940128
Table 4 Differences in distributions of examined variables among quartiles of IL-17A. Numerical variables.
| Variable | 1st quartile39 records | 2nd quartile46 records | 3rd quartile40 records | 4th quartile45 records | p-value | Post hoc test (Quartile combinations and adjusted p-value) |
|---|---|---|---|---|---|---|
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 2.43 (1.21) | 2.51 (1.12) | 2.40 (1.08) | 2.58 (1.36) | 0.80* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 4.10 (1.34) | 3.97 (1.30) | 3.97 (1.28) | 3.95 (1.45) | 0.80* | |
| (St p-value >0.05, a normal distribution) – Mean (SD) | 34.99 (8.19) | 33.20 (9.49) | 34.27 (7.52) | 34.69 (9.23) | 0.78** | |
| (St p-value >0.05, a normal distribution) – Mean (SD) | 52.99 (7.60) | 53.49 (8.04) | 52.77 (8.17) | 52.92 (9.69) | 0.98** | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 1.60 (0.90) | 1.69 (1.10) | 1.60 (0.62) | 1.60 (1.05) | 0.93* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 2.00 (1.70) | 1.85 (1.80) | 1.80 (3.43) | 1.90 (3.40) | 0.30* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 80.00 (29.00) | 86.00 (35.00) | 80.50 (33.00) | 82.00 (44.00) | 0.54* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 67.00 (10.00) | 63.00 (10.75) | 70.00 (9.00) | 65.00 (12.00) | 0.08 (0.02 – small effect)* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 103.0 (11.50) | 104.00 (14.00) | 102.50 (11.25) | 103.00 (11.00) | 0.88* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 30.00 (4.00) | 30.00 (3.00) | 29.00 (2.25) | 31.00 (3.00) | 0.22* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 9.00 (10.00) | 9.00 (9.00) | 6.50 (10.50) | 8.00 (11.00) | 0.96* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 8.00 (8.00) | 8.00 (9.50) | 8.50 (7.00) | 8.00 (7.00) | 0.66* | |
| (St p-value >0.05, a normal distribution) – Mean (SD) | 7.65 (1.63) | 7.24 (1.47) | 7.41 (1.74) | 8.00 (2.14) | 0.20** | |
| (St p-value >0.05, a normal distribution) – Mean (SD) | 4.80 (0.47) | 4.78 (0.47) | 4.89 (0.37) | 4.69 (0.44) | 0.20** | |
| (St p-value >0.05, a normal distribution) – Mean (SD) | 3.51 (0.82) | 3.05 (1.10) | 2.91 (1.08) | 3.39 (1.06) | (0.05 – medium effect)** | Q1–Q3 (0.05)*** |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 1.29 (0.30) | 1.33 (0.40) | 1.32 (0.42) | 1.37 (0.42) | 0.45* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 146.00 (18.00) | 143.50 (19.00) | 147.00 (14.75) | 137.00 (16.00) | (0.04 – small effect)* | Q3–Q4 (0.02) |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 7.00 (2.60) | 8.45 (2.58) | 8.95 (3.15) | 7.70 (3.10) | (0.03 – small effect)* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 6.60 (1.20) | 7.00 (1.73) | 7.60 (1.90) | 6.80 (1.20) | (0.04 – small effect)* | Q1–Q3 (0.05) |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 1.80 (0.80) | 1.75 (1.16) | 1.60 (0.79) | 1.77 (0.92) | 0.46* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 5.40 (1.60) | 5.20 (1.83) | 4.75 (1.63) | 5.20 (1.20) | 0.35* | |
| (St p-value <0.05, not a normal distribution) – Median (IQR) | 2.40 (1.49) | 2.42 (1.84) | 3.10 (1.60) | 2.39 (1.80) | 0.30* | |
| St – Shapiro test normality; * Kruskal-Wallis rank sum test; ** ANOVA test (Bartlett’s test for testing homogeneity of variances); *** ANOVA post hoc test (Tukey’s test); ***** KW post hoc test (Dunn’s test with a Bonferroni correction). | ||||||